256 related articles for article (PubMed ID: 33185747)
1. Sapap3 deletion causes dynamic synaptic density abnormalities: a longitudinal [
Glorie D; Verhaeghe J; Miranda A; De Lombaerde S; Stroobants S; Staelens S
EJNMMI Res; 2020 Nov; 10(1):140. PubMed ID: 33185747
[TBL] [Abstract][Full Text] [Related]
2. Progression of obsessive compulsive disorder-like grooming in Sapap3 knockout mice: A longitudinal [
Glorie D; Verhaeghe J; Miranda A; Kertesz I; Wyffels L; Stroobants S; Staelens S
Neuropharmacology; 2020 Oct; 177():108160. PubMed ID: 32454126
[TBL] [Abstract][Full Text] [Related]
3. Circuit-selective striatal synaptic dysfunction in the Sapap3 knockout mouse model of obsessive-compulsive disorder.
Wan Y; Ade KK; Caffall Z; Ilcim Ozlu M; Eroglu C; Feng G; Calakos N
Biol Psychiatry; 2014 Apr; 75(8):623-30. PubMed ID: 23414593
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and Preclinical Evaluation of 11C-UCB-J as a PET Tracer for Imaging the Synaptic Vesicle Glycoprotein 2A in the Brain.
Nabulsi NB; Mercier J; Holden D; Carré S; Najafzadeh S; Vandergeten MC; Lin SF; Deo A; Price N; Wood M; Lara-Jaime T; Montel F; Laruelle M; Carson RE; Hannestad J; Huang Y
J Nucl Med; 2016 May; 57(5):777-84. PubMed ID: 26848175
[TBL] [Abstract][Full Text] [Related]
5. Synaptic Vesicle Glycoprotein 2A Is Affected in the Central Nervous System of Mice with Huntington Disease and in the Brain of a Human with Huntington Disease Postmortem.
Bertoglio D; Verhaeghe J; Wyffels L; Miranda A; Stroobants S; Mrzljak L; Dominguez C; Skinbjerg M; Bard J; Liu L; Munoz-Sanjuan I; Staelens S
J Nucl Med; 2022 Jun; 63(6):942-947. PubMed ID: 34531262
[TBL] [Abstract][Full Text] [Related]
6. Development and In Vivo Preclinical Imaging of Fluorine-18-Labeled Synaptic Vesicle Protein 2A (SV2A) PET Tracers.
Constantinescu CC; Tresse C; Zheng M; Gouasmat A; Carroll VM; Mistico L; Alagille D; Sandiego CM; Papin C; Marek K; Seibyl JP; Tamagnan GD; Barret O
Mol Imaging Biol; 2019 Jun; 21(3):509-518. PubMed ID: 30084043
[TBL] [Abstract][Full Text] [Related]
7. Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging.
Chen MK; Mecca AP; Naganawa M; Finnema SJ; Toyonaga T; Lin SF; Najafzadeh S; Ropchan J; Lu Y; McDonald JW; Michalak HR; Nabulsi NB; Arnsten AFT; Huang Y; Carson RE; van Dyck CH
JAMA Neurol; 2018 Oct; 75(10):1215-1224. PubMed ID: 30014145
[TBL] [Abstract][Full Text] [Related]
8. In vivo imaging of synaptic SV2A protein density in healthy and striatal-lesioned rats with [11C]UCB-J PET.
Thomsen MB; Jacobsen J; Lillethorup TP; Schacht AC; Simonsen M; Romero-Ramos M; Brooks DJ; Landau AM
J Cereb Blood Flow Metab; 2021 Apr; 41(4):819-830. PubMed ID: 32538280
[TBL] [Abstract][Full Text] [Related]
9. Preclinical PET Studies of [
Thomsen MB; Schacht AC; Alstrup AKO; Jacobsen J; Lillethorup TP; Bærentzen SL; Noer O; Orlowski D; Elfving B; Müller HK; Brooks DJ; Landau AM
Mol Imaging Biol; 2020 Oct; 22(5):1290-1300. PubMed ID: 32514885
[TBL] [Abstract][Full Text] [Related]
10. Validation of Parametric Methods for [
Mertens N; Maguire RP; Serdons K; Lacroix B; Mercier J; Sciberras D; Van Laere K; Koole M
Mol Imaging Biol; 2020 Apr; 22(2):444-452. PubMed ID: 31209780
[TBL] [Abstract][Full Text] [Related]
11. In vivo imaging of synaptic density with [
Xiong M; Roshanbin S; Rokka J; Schlein E; Ingelsson M; Sehlin D; Eriksson J; Syvänen S
Neuroimage; 2021 Oct; 239():118302. PubMed ID: 34174391
[TBL] [Abstract][Full Text] [Related]
12. SV2A PET Imaging Is a Noninvasive Marker for the Detection of Spinal Damage in Experimental Models of Spinal Cord Injury.
Bertoglio D; Halloin N; Lombaerde S; Jankovski A; Verhaeghe J; Nicaise C; Staelens S
J Nucl Med; 2022 Aug; 63(8):1245-1251. PubMed ID: 35027368
[TBL] [Abstract][Full Text] [Related]
13. Projection-specific deficits in synaptic transmission in adult Sapap3-knockout mice.
Hadjas LC; Schartner MM; Cand J; Creed MC; Pascoli V; Lüscher C; Simmler LD
Neuropsychopharmacology; 2020 Nov; 45(12):2020-2029. PubMed ID: 32585679
[TBL] [Abstract][Full Text] [Related]
14. Identification of pre-synaptic density networks using [
Akkermans J; Zajicek F; Miranda A; Adhikari MH; Bertoglio D
Neuroimage; 2022 Dec; 264():119771. PubMed ID: 36436710
[TBL] [Abstract][Full Text] [Related]
15. Validation and noninvasive kinetic modeling of [
Bertoglio D; Verhaeghe J; Miranda A; Kertesz I; Cybulska K; Korat Š; Wyffels L; Stroobants S; Mrzljak L; Dominguez C; Liu L; Skinbjerg M; Munoz-Sanjuan I; Staelens S
J Cereb Blood Flow Metab; 2020 Jun; 40(6):1351-1362. PubMed ID: 31307287
[TBL] [Abstract][Full Text] [Related]
16. In Vivo Synaptic Density Imaging with
Toyonaga T; Smith LM; Finnema SJ; Gallezot JD; Naganawa M; Bini J; Mulnix T; Cai Z; Ropchan J; Huang Y; Strittmatter SM; Carson RE
J Nucl Med; 2019 Dec; 60(12):1780-1786. PubMed ID: 31101744
[No Abstract] [Full Text] [Related]
17. Synaptic density in healthy human aging is not influenced by age or sex: a
Michiels L; Delva A; van Aalst J; Ceccarini J; Vandenberghe W; Vandenbulcke M; Koole M; Lemmens R; Laere KV
Neuroimage; 2021 May; 232():117877. PubMed ID: 33639258
[TBL] [Abstract][Full Text] [Related]
18. Strengthened Inputs from Secondary Motor Cortex to Striatum in a Mouse Model of Compulsive Behavior.
Corbit VL; Manning EE; Gittis AH; Ahmari SE
J Neurosci; 2019 Apr; 39(15):2965-2975. PubMed ID: 30737313
[TBL] [Abstract][Full Text] [Related]
19. Preclinical In Vitro and In Vivo Characterization of Synaptic Vesicle 2A-Targeting Compounds Amenable to F-18 Labeling as Potential PET Radioligands for Imaging of Synapse Integrity.
Patel S; Knight A; Krause S; Teceno T; Tresse C; Li S; Cai Z; Gouasmat A; Carroll VM; Barret O; Gottmukkala V; Zhang W; Xiang X; Morley T; Huang Y; Passchier J
Mol Imaging Biol; 2020 Aug; 22(4):832-841. PubMed ID: 31728839
[TBL] [Abstract][Full Text] [Related]
20. Autoradiographic mapping of synaptic vesicle glycoprotein 2A in non-human primate and human brain.
Varnäs K; Stepanov V; Halldin C
Synapse; 2020 Oct; 74(10):e22157. PubMed ID: 32259300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
